![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_7ce5c90b273b41810bee3170ac9401d3.svg) | Haloperidol | IC50 | 0.06 [1], 10.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_7ce5c90b273b41810bee3170ac9401d3.svg) | Haloperidol | Ki | 4.4 [1], 4.6 [2], 10.4 [3], 18.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_8159b09a6bebd9e5751360e57f770ab8.svg) | Clozapine | IC50 | 450.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_8159b09a6bebd9e5751360e57f770ab8.svg) | Clozapine | Ki | 240.0 [1], 242.0 [2], 319.0 [3], 513.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_4f1ecda65187979a1ede67e5fe1e057c.svg) | Quinpirole | Ki | 23.99 [1], 24.0 [2], 420.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_15ca575feede8d82e6e415c2062eee56.svg) | 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine | Ki | 5300.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_6cf5ecbb9a1c42bdc42ce186d840229c.svg) | 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)- | IC50 | 3.0 [1], 13.0 [2], 56.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_6cf5ecbb9a1c42bdc42ce186d840229c.svg) | 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)- | Ki | 0.92 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_a299b1d13d869af4b861f59c43b5579a.svg) | N-[4-[2-(6-Cyano-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]cyclohexyl]quinoline-4-carboxamide | Ki | 11.2 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_135e1b51c4285a8ab5ce02f8e0f91fbe.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-1-benzothiophene-2-carboxamide | IC50 | 4.94 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_135e1b51c4285a8ab5ce02f8e0f91fbe.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-1-benzothiophene-2-carboxamide | Ki | 0.5 [1], 0.8 [2], 2.6 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_8b78ef0953132cb6729f40caa0d6bbea.svg) | Olanzapine | Ki | 39.0 [1], 43.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_f2c8cfca26d08d9cddd0a351dd654443.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-9H-fluorene-2-carboxamide | IC50 | 5.0 [1], 14.4 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_f2c8cfca26d08d9cddd0a351dd654443.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-9H-fluorene-2-carboxamide | Ki | 2.0 [1], 2.7 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_be4565ca8c20c1d9804fa640fd1584d5.svg) | Risperidone | Ki | 16.0 [1], 31.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_14ad78f21aebf7ef75d24ea25f5fe082.svg) | 3-((4-(4-Chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine | Ki | 2310.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_7e3c87574db588f1ff3e2334e06ef74b.svg) | 3-[[4-(4-Chlorophenyl)piperazin-1-yl]methyl]pyrazolo[1,5-a]pyridine | Ki | 5000.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_bcbb36a6cad84298c3dc74af8f90788c.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)benzofuran-2-carboxamide | IC50 | 9.01 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_bcbb36a6cad84298c3dc74af8f90788c.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)benzofuran-2-carboxamide | Ki | 0.8 [1], 1.5 [2], 4.3 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_f25dfa08591eac4ad2095b30ced84e29.svg) | Spiperone | IC50 | 0.36 [1], 93.2 [2], 97.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_f25dfa08591eac4ad2095b30ced84e29.svg) | Spiperone | Ki | 1.31 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_755ee1e8383f829eee41205704ba0ef5.svg) | US8748608, 34 Enantiomer A | IC50 | 29.9 [1], 30.0 [2], 495.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_12815b9751dbf5582561f8504a6ddde7.svg) | N-[4-[4-[2-Tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]imidazo[1,2-a]pyridine-2-carboxamide | IC50 | 0.6 [1], 1.3 [2], 157.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_d24fe0e15c6ed43cc236ee350bd5c850.svg) | Pramipexole | Ki | 0.72 [1], 0.88 [2], 38.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_8d00c7e96474ff312d9793fb99a79721.svg) | 7-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-2-ol | Ki | 1.4 [1], 2.9 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_539379af00d28d52ac3e09d6c762f691.svg) | 3-(4-(4-Chlorophenyl-4-hydroxypiperidino)methyl)indole | IC50 | 90.4 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_77e4af059cc4b18b86801899a8e5718a.svg) | CID 11477180 | IC50 | 3.0 [1], 3.01 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_77e4af059cc4b18b86801899a8e5718a.svg) | CID 11477180 | Ki | 0.7 [1], 2.11 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_4029cddb9feea6760cc48d0f9cf81c60.svg) | 7-Dipropylamino-5,6,7,8-tetrahydro-naphthalen-2-ol | Ki | 0.79 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_2b9dace88de32f2fcc2422f830a67192.svg) | N-[4-[4-[2-Tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-5-[(dimethylamino)methyl]imidazo[1,2-a]pyridine-2-carboxamide | IC50 | 29.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_652934e6d05a1d1ee1aa17f2688dc668.svg) | N-[4-[4-[2-Tert-butyl-6-(trifluoromethyl)pyrimidin-4-yl]piperazin-1-yl]butyl]-3-[(dimethylamino)methyl]imidazo[1,2-a]pyridine-2-carboxamide | IC50 | 7.2 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_421b8d1934e3715ea1028700fe65fa1f.svg) | N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)benzo[b]thiophene-2-carboxamide | IC50 | 0.22 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_421b8d1934e3715ea1028700fe65fa1f.svg) | N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)benzo[b]thiophene-2-carboxamide | Ki | 0.19 [1], 0.23 [2], 0.27 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_0a134c7bdfe8bb6ecd77b0a4423ba759.svg) | (R)-N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide | IC50 | 18.2 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_0a134c7bdfe8bb6ecd77b0a4423ba759.svg) | (R)-N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)-3-hydroxybutyl)-1H-indole-2-carboxamide | Ki | 0.53 [1], 1.12 [2], 2.9 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_96a9bdb79c4ed0a3e31c53982f1e7a6f.svg) | 4-[3-(4-Chlorophenyl)-3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl]-1-(4-fluorophenyl)butan-1-one | Ki | 0.71 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_63496733a2ee7161ee3d52683fdaf225.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)but-2-enyl)-9H-fluorene-2-carboxamide | IC50 | 173.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_63496733a2ee7161ee3d52683fdaf225.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)but-2-enyl)-9H-fluorene-2-carboxamide | Ki | 1.5 [1], 5.0 [2], 5.9 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5e0d4c843131f068185294b41a13c5c4.svg) | (S)-7-Dipropylamino-5,6,7,8-tetrahydro-indolizine-3-carbaldehyde | Ki | 5.25 [1], 5.3 [2], 150.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_bce845d436bf481476e96170d5d54e15.svg) | N-[(E)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]-1-benzothiophene-2-carboxamide | IC50 | 9.62 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_bce845d436bf481476e96170d5d54e15.svg) | N-[(E)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]-1-benzothiophene-2-carboxamide | Ki | 1.1 [1], 1.11 [2], 3.3 [3], 1770.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_fca76485e17be803b3cb63e3f759826d.svg) | N-[(E)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]-1-benzofuran-2-carboxamide | IC50 | 18.7 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_fca76485e17be803b3cb63e3f759826d.svg) | N-[(E)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]but-2-enyl]-1-benzofuran-2-carboxamide | Ki | 2.1 [1], 2.11 [2], 7.11 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_6f84775f6accb5daab619b684843e61c.svg) | Sulpiride | IC50 | 66.22 [1], 560.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_6f84775f6accb5daab619b684843e61c.svg) | Sulpiride | Ki | 8.0 [1], 57.0 [2], 120.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_1702ec4e91a6e6ac7ec0735114adb8a6.svg) | Ziprasidone | Ki | 6.31 [1], 7.2 [2], 7.5 [3], 10.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_572032fb3d3bef05fc2d30862cc4e78d.svg) | (+)-Butaclamol | IC50 | 1.6 [1], 16.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_572032fb3d3bef05fc2d30862cc4e78d.svg) | (+)-Butaclamol | Ki | 0.04 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5d04839800fb36d0809dc154554e3949.svg) | Butaclamol | IC50 | 1.2 [1], 1.9 [2], 6.6 [3], 10.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5d04839800fb36d0809dc154554e3949.svg) | Butaclamol | Ki | 6.39 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5c42390fbf32be570a65ea31c2c84cfa.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide | IC50 | 6.31 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5c42390fbf32be570a65ea31c2c84cfa.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide | Ki | 0.4 [1], 0.5 [2], 2.33 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_760c170bad01a1c163e866a9dbce9f05.svg) | N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)benzofuran-2-carboxamide | IC50 | 2.39 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_760c170bad01a1c163e866a9dbce9f05.svg) | N-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butyl)benzofuran-2-carboxamide | Ki | 0.92 [1], 1.1 [2], 1.12 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_13e7b8caa6f0639517c7c1e44490574b.svg) | N-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-benzamide | IC50 | 7.71 [1], 7.72 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_13e7b8caa6f0639517c7c1e44490574b.svg) | N-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-but-2-enyl}-benzamide | Ki | 0.8 [1], 6.02 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_aad7174f0cd154de8f73133e761e0d3a.svg) | N-[4-[(4-Ethynylcyclohex-3-en-1-yl)-propylamino]butyl]-4-phenylbenzamide | Ki | 0.2 [1], 0.21 [2], 0.78 [3], 20.0 [4], 870.0 [5] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_75ea87d1833a17b99edbf00c777dad9a.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]quinoxaline-2-carboxamide | IC50 | 26.8 [1], 26.9 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_75ea87d1833a17b99edbf00c777dad9a.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]quinoxaline-2-carboxamide | Ki | 1.4 [1], 10.6 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_156dfe85e360ca8079d7ddff067a9739.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-3-fluorobutyl]-1-benzofuran-2-carboxamide | IC50 | 430.0 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_156dfe85e360ca8079d7ddff067a9739.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-3-fluorobutyl]-1-benzofuran-2-carboxamide | Ki | 5.4 [1], 6.1 [2], 10.0 [3], 31.5 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_97a19aaf0d5543f1913f8ce699f59cb1.svg) | 2-[5-[4-(4-Chlorophenyl)piperazin-1-yl]pentyl]pyrazolo[1,5-a]pyridine | Ki | 220.0 [1], 370.0 [2], 530.0 [3], 1100.0 [4], 1900.0 [5] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_3e94330ba1527a829fecddbee5acde55.svg) | Apomorphine | Ki | 2.6 [1], 7.8 [2], 10.0 [3], 17.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_1cc2b60cca4e323ddf9ecdbc35b6e60e.svg) | Ropinirole | Ki | 2.9 [1], 19.0 [2], 36.31 [3], 61.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_6b6e0d481187acf8847f8c2083bf7a99.svg) | Preclamol | Ki | 25.0 [1], 25.12 [2], 132.0 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_8873e7c98d1d6dd57f09c4a8cd059afc.svg) | Cariprazine | Ki | 0.09 [1], 0.1 [2], 0.27 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_2b9338803c8da7a9eb261bc345ef6993.svg) | 5-OH-Dpat | Ki | 0.66 [1], 1.36 [2], 4.4 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_e8138dcbce34118e33bd4b23c56e1801.svg) | (1S,2R)-5-Methoxy-1-methyl-N,N-dipropyl-1,2,3,4-tetrahydronaphthalen-2-amine | Ki | 4.0 [1], 4.2 [2], 12.59 [3] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_5d130d7ecaa414145a8b69a09a067e5a.svg) | Sumanirole | Ki | 546.0 [1], 573.0 [2], 2333.0 [3], 6330.0 [4] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_c01a6b3d063d97c54b4faccdab41fca4.svg) | 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole | Ki | 480.0 [1], 770.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_fc8bdd1583fe377dfcd4f750b5c85857.svg) | N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)-1H-indole-2-carboxamide | Ki | 0.66 [1], 1.4 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_423b81e49046b6b59498c10bdf1ee695.svg) | 11-Methyl-11-azatricyclo[12.4.0.03,8]octadeca-1(18),3(8),4,6,14,16-hexaen-6-ol | Ki | 47.0 [1], 47.5 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_d944deb6914f8204bd7dfa354dd1ae6a.svg) | 4-Methyl-5-[4-methyl-5-[3-[1-[4-(trifluoromethyl)phenyl]-3-azabicyclo[3.1.0]hexan-3-yl]propylsulfanyl]-1,2,4-triazol-3-yl]-1,3-oxazole | Ki | 0.5 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_51220e5472d66adf06def2d15af29345.svg) | N-[(3S)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-3-hydroxybutyl]-1H-indole-2-carboxamide | IC50 | 6.6 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_51220e5472d66adf06def2d15af29345.svg) | N-[(3S)-4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]-3-hydroxybutyl]-1H-indole-2-carboxamide | Ki | 3.9 [1], 16.6 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_00bb7a17cf91a213239d3dabcbaea8f0.svg) | N-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butyl}-4-iodo-benzamide | IC50 | 31.7 [1] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_00bb7a17cf91a213239d3dabcbaea8f0.svg) | N-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butyl}-4-iodo-benzamide | Ki | 1.6 [1], 3.0 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_21a51289494f12ccb788de3c2de40712.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-5-fluoro-1H-indole-2-carboxamide | IC50 | 52.0 [1], 52.4 [2] |
![](https://images.aatbio.com/dataset/ic50/dopamine-d3-receptor_21a51289494f12ccb788de3c2de40712.svg) | N-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butyl]-5-fluoro-1H-indole-2-carboxamide | Ki | 0.28 [1], 0.52 [2] |